RecruitingRecruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 · Ruijin Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-grazytracer PET/CT after 3 cycles of immunotherapy to evaluate response. The imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.
Eligibility criteria
Inclusion Criteria:
1. Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
2. Signed and dated informed consent form
3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \> 6 months
Exclusion Criteria:
1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Intestinal perforation, complete intestinal obstruction
3. Pregnant women and women who may be pregnant, women who are breastfeeding.
4. Non-compliant person
Study design
Enrollment target: 30 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-09-24
Estimated completion: 2027-08-31
Last updated: 2024-12-11
Primary outcomes
- • Evaluation the responses to immunotherapy of pancreatic cancer (up to about 10 weeks)
- • Standardized uptake value(SUV) (up to about 10 weeks)
- • Target-to-background ratio(TBR) (up to about 10 weeks)
Sponsor
Ruijin Hospital · other
Contacts & investigators
ContactJiajia Hu · contact · jiajiahu@shsmu.edu.cn · 13524945287
All locations (1)
Ruijin Hospital affiliated to Shanghai Jiao Tong University of MedicineRecruiting
Shanghai, Shanghai Municipality, China